216 related articles for article (PubMed ID: 12003183)
1. Anticancer activity and protein phosphatase 1 and 2A inhibition of a new generation of cantharidin analogues.
Sakoff JA; Ackland SP; Baldwin ML; Keane MA; McCluskey A
Invest New Drugs; 2002 Feb; 20(1):1-11. PubMed ID: 12003183
[TBL] [Abstract][Full Text] [Related]
2. Anhydride modified cantharidin analogues: synthesis, inhibition of protein phosphatases 1 and 2A and anticancer activity.
McCluskey A; Bowyer MC; Collins E; Sim ATR ; Sakoff JA; Baldwin ML
Bioorg Med Chem Lett; 2000 Aug; 10(15):1687-90. PubMed ID: 10937725
[TBL] [Abstract][Full Text] [Related]
3. Heterocyclic substituted cantharidin and norcantharidin analogues--synthesis, protein phosphatase (1 and 2A) inhibition, and anti-cancer activity.
Hill TA; Stewart SG; Sauer B; Gilbert J; Ackland SP; Sakoff JA; McCluskey A
Bioorg Med Chem Lett; 2007 Jun; 17(12):3392-7. PubMed ID: 17451951
[TBL] [Abstract][Full Text] [Related]
4. Cantharidin analogues: synthesis and evaluation of growth inhibition in a panel of selected tumour cell lines.
McCluskey A; Ackland SP; Bowyer MC; Baldwin ML; Garner J; Walkom CC; Sakoff JA
Bioorg Chem; 2003 Feb; 31(1):68-79. PubMed ID: 12697169
[TBL] [Abstract][Full Text] [Related]
5. Serine/threonine protein phosphatase inhibition enhances the effect of thymidylate synthase inhibition.
Sakoff JA; Howitt IJ; Ackland SP; McCluskey A
Cancer Chemother Pharmacol; 2004 Mar; 53(3):225-32. PubMed ID: 14648018
[TBL] [Abstract][Full Text] [Related]
6. Cantharimides: a new class of modified cantharidin analogues inhibiting protein phosphatases 1 and 2A.
McCluskey A; Walkom C; Bowyer MC; Ackland SP; Gardiner E; Sakoff JA
Bioorg Med Chem Lett; 2001 Nov; 11(22):2941-6. PubMed ID: 11677131
[TBL] [Abstract][Full Text] [Related]
7. Norcantharidin analogues: synthesis, anticancer activity and protein phosphatase 1 and 2A inhibition.
Hill TA; Stewart SG; Gordon CP; Ackland SP; Gilbert J; Sauer B; Sakoff JA; McCluskey A
ChemMedChem; 2008 Dec; 3(12):1878-92. PubMed ID: 19025735
[TBL] [Abstract][Full Text] [Related]
8. Anhydride modified cantharidin analogues. Is ring opening important in the inhibition of protein phosphatase 2A?
McCuskey A; Keane MA; Mudgee LM; Sim AT; Sakoff J; Quinn RJ
Eur J Med Chem; 2000 Oct; 35(10):957-64. PubMed ID: 11121622
[TBL] [Abstract][Full Text] [Related]
9. The first two cantharidin analogues displaying PP1 selectivity.
McCluskey A; Keane MA; Walkom CC; Bowyer MC; Sim AT; Young DJ; Sakoff JA
Bioorg Med Chem Lett; 2002 Feb; 12(3):391-3. PubMed ID: 11814804
[TBL] [Abstract][Full Text] [Related]
10. The inhibition of protein phosphatases 1 and 2A: a new target for rational anti-cancer drug design?
McCluskey A; Ackland SP; Gardiner E; Walkom CC; Sakoff JA
Anticancer Drug Des; 2001 Dec; 16(6):291-303. PubMed ID: 12375882
[TBL] [Abstract][Full Text] [Related]
11. Cytotoxicity of cantharidin analogues targeting protein phosphatase 2A.
Shan HB; Cai YC; Liu Y; Zeng WN; Chen HX; Fan BT; Liu XH; Xu ZL; Wang B; Xian LJ
Anticancer Drugs; 2006 Sep; 17(8):905-11. PubMed ID: 16940800
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic effects of cantharidin analogues without bridging ether oxygen on human hepatocellular carcinoma cells.
Yeh CB; Su CJ; Hwang JM; Chou MC
Eur J Med Chem; 2010 Sep; 45(9):3981-5. PubMed ID: 20691337
[TBL] [Abstract][Full Text] [Related]
13. Protein phosphatase 2A and its [3H]cantharidin/[3H]endothall thioanhydride binding site. Inhibitor specificity of cantharidin and ATP analogues.
Li YM; Mackintosh C; Casida JE
Biochem Pharmacol; 1993 Oct; 46(8):1435-43. PubMed ID: 8240393
[TBL] [Abstract][Full Text] [Related]
14. The effects of cantharidin and cantharidin derivates on tumour cells.
Liu D; Chen Z
Anticancer Agents Med Chem; 2009 May; 9(4):392-6. PubMed ID: 19442040
[TBL] [Abstract][Full Text] [Related]
15. Modified norcantharidins; synthesis, protein phosphatases 1 and 2A inhibition, and anticancer activity.
Hart ME; Chamberlin AR; Walkom C; Sakoff JA; McCluskey A
Bioorg Med Chem Lett; 2004 Apr; 14(8):1969-73. PubMed ID: 15050639
[TBL] [Abstract][Full Text] [Related]
16. Overview of Cantharidin and its Analogues.
Wang G; Dong J; Deng L
Curr Med Chem; 2018; 25(17):2034-2044. PubMed ID: 28413963
[TBL] [Abstract][Full Text] [Related]
17. Cantharidin, another natural toxin that inhibits the activity of serine/threonine protein phosphatases types 1 and 2A.
Honkanen RE
FEBS Lett; 1993 Sep; 330(3):283-6. PubMed ID: 8397101
[TBL] [Abstract][Full Text] [Related]
18. Fostriecin-mediated G2-M-phase growth arrest correlates with abnormal centrosome replication, the formation of aberrant mitotic spindles, and the inhibition of serine/threonine protein phosphatase activity.
Cheng A; Balczon R; Zuo Z; Koons JS; Walsh AH; Honkanen RE
Cancer Res; 1998 Aug; 58(16):3611-9. PubMed ID: 9721869
[TBL] [Abstract][Full Text] [Related]
19. Cantharidin, a potent and selective PP2A inhibitor, induces an oxidative stress-independent growth inhibition of pancreatic cancer cells through G2/M cell-cycle arrest and apoptosis.
Li W; Xie L; Chen Z; Zhu Y; Sun Y; Miao Y; Xu Z; Han X
Cancer Sci; 2010 May; 101(5):1226-33. PubMed ID: 20331621
[TBL] [Abstract][Full Text] [Related]
20. Antitumor potential of the protein phosphatase inhibitor, cantharidin, and selected derivatives.
Ren Y; Kinghorn AD
Bioorg Med Chem; 2021 Feb; 32():116012. PubMed ID: 33454654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
